“There’s a lot of work to do in MAT. Although MAT is an evidence-based practice, more and more questions are surfacing around how to deliver it in the real world to improve outcomes. Questions like:
- How can we offer MAT to a broader population?
- Which patients are best suited to which medications?
- Which patients are best suited to which treatment settings?
- What are the best guidelines to use around dose, duration, monitoring, and concurrent psychosocial treatment?
Research and practice in this area are both moving and changing quickly. Buprenorphine (Suboxone, Subutex) for opioid dependence has exploded onto the market (half a million people now use it) and has been joined by naltrexone for opioid and alcohol dependence. Other addiction medications are right on their tails. Human testing for a cocaine vaccine is expected to begin within a year.
Amid this flurry, in the last two years, IRETA has created treatment practice guidelines in two areas—how to use buprenorphine for opioid dependence treatment and how to manage patient benzodiazepine use in MAT. We’ve been able to do that using the RAM.”
Source: IRETA.org – May 31, 2013